JP2017535601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535601A5 JP2017535601A5 JP2017543329A JP2017543329A JP2017535601A5 JP 2017535601 A5 JP2017535601 A5 JP 2017535601A5 JP 2017543329 A JP2017543329 A JP 2017543329A JP 2017543329 A JP2017543329 A JP 2017543329A JP 2017535601 A5 JP2017535601 A5 JP 2017535601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- apilimod
- therapeutic
- renal
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| PCT/US2015/059512 WO2016073877A1 (en) | 2014-11-07 | 2015-11-06 | Apilimod for use in the treatment of renal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535601A JP2017535601A (ja) | 2017-11-30 |
| JP2017535601A5 true JP2017535601A5 (enExample) | 2018-12-13 |
| JP6705828B2 JP6705828B2 (ja) | 2020-06-03 |
Family
ID=54548302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543329A Expired - Fee Related JP6705828B2 (ja) | 2014-11-07 | 2015-11-06 | 腎癌の処置に使用するためのアピリモド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10206910B2 (enExample) |
| EP (2) | EP3215158B1 (enExample) |
| JP (1) | JP6705828B2 (enExample) |
| KR (1) | KR20170098812A (enExample) |
| CN (1) | CN107249638B (enExample) |
| AU (1) | AU2015342869A1 (enExample) |
| BR (1) | BR112017008799A2 (enExample) |
| CA (1) | CA2966359A1 (enExample) |
| ES (1) | ES2741399T3 (enExample) |
| HU (1) | HUE044557T2 (enExample) |
| IL (1) | IL251905B (enExample) |
| MX (1) | MX377593B (enExample) |
| PL (1) | PL3215158T3 (enExample) |
| PT (1) | PT3215158T (enExample) |
| RU (1) | RU2727802C2 (enExample) |
| WO (1) | WO2016073877A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179135B2 (en) | 2014-01-24 | 2019-01-15 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| BR112017008799A2 (pt) | 2014-11-07 | 2017-12-19 | Lam Therapeutics Inc | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal |
| CN107427522B (zh) * | 2014-11-07 | 2021-06-15 | 人工智能治疗公司 | 用于治疗黑素瘤的阿吡莫德 |
| EP3405199A1 (en) * | 2016-01-21 | 2018-11-28 | LAM Therapeutics, Inc. | Biomarkers for treating cancer with apilimod |
| AU2017316475A1 (en) * | 2016-08-25 | 2019-03-07 | AI Therapeutics, Inc. | Compositions comprising PIKfyve inhibitors and methods related to inhibition of rank signaling |
| AU2017342262B2 (en) * | 2016-10-12 | 2023-09-28 | Orphai Therapeutics Inc. | Apilimod compositions and methods for using same in the treatment of alzheimer's disease |
| WO2018175906A1 (en) | 2017-03-24 | 2018-09-27 | Nanosyn, Inc. | Fused triazolo-pyrimidine compounds having useful pharmaceutical application |
| IL310376B1 (en) | 2018-01-26 | 2025-10-01 | Univ California | Methods and compositions for treating angiogenic disorders using anti-VEGF factors |
| RU2020130837A (ru) | 2018-02-21 | 2022-03-21 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Комбинационная терапия апилимодом и глутаматергическими агентами |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| PH12022551623A1 (en) | 2020-01-13 | 2023-11-29 | Verge Analytics Inc | Substituted pyrazolo-pyrimidines and uses thereof |
| CN114306370A (zh) * | 2021-12-31 | 2022-04-12 | 北京悦康科创医药科技股份有限公司 | 反义寡核苷酸在制备治疗肾癌药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| EP1921169B1 (en) | 1993-11-12 | 2012-02-15 | PHRI Properties, Inc. | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| MXPA06008746A (es) | 2004-02-06 | 2007-01-23 | Elan Pharm Inc | Metodos y composiciones para tratamiento de tumores y enfermedad metastatica. |
| WO2005112938A2 (en) | 2004-04-13 | 2005-12-01 | Synta Pharmaceuticals Corp. | Disalt inhibitors of il-12 production |
| CA2579096C (en) | 2004-09-08 | 2012-11-13 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds |
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| EA015463B1 (ru) | 2005-11-17 | 2011-08-30 | Оси Фармасьютикалз, Инк. | КОНДЕНСИРОВАННОЕ БИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ - ИНГИБИТОР mTOR, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ РАКА |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| JP5156644B2 (ja) | 2006-01-25 | 2013-03-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 不飽和ｍＴＯＲ阻害剤 |
| EA031888B1 (ru) | 2006-07-12 | 2019-03-29 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Способы применения замещенных ациланилидов |
| MX2009008341A (es) | 2007-02-06 | 2009-08-12 | Novartis Ag | Inhibidores de cinasa de pi3 y metodos para su uso. |
| RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| DE102007036076A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP5258331B2 (ja) | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| EP3338770B1 (en) | 2010-03-08 | 2023-06-07 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| CN102905707A (zh) * | 2010-03-29 | 2013-01-30 | 味之素株式会社 | 含有苯基丙氨酸衍生物的医药制剂 |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| US20110287018A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of Treating Interstitial Cystitis |
| US8709419B2 (en) * | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| JP6061346B2 (ja) | 2010-11-19 | 2017-01-18 | エコール ポリテクニーク フェデラル ドゥ ローザンヌ （イーピーエフエル） | ２−ピペラジン−１−イル−４ｈ−１，３−ベンゾチアジン−４−オン誘導体、および哺乳類の感染症治療へのその使用 |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| US10179135B2 (en) | 2014-01-24 | 2019-01-15 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| CN107427522B (zh) | 2014-11-07 | 2021-06-15 | 人工智能治疗公司 | 用于治疗黑素瘤的阿吡莫德 |
| BR112017008799A2 (pt) | 2014-11-07 | 2017-12-19 | Lam Therapeutics Inc | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal |
| KR101761573B1 (ko) | 2014-12-29 | 2017-07-26 | 주식회사 인트론바이오테크놀로지 | 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도 |
| WO2016126707A1 (en) | 2015-02-03 | 2016-08-11 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
| WO2016160102A1 (en) | 2015-03-31 | 2016-10-06 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| AU2019299234A1 (en) | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
| US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-11-06 BR BR112017008799A patent/BR112017008799A2/pt not_active Application Discontinuation
- 2015-11-06 AU AU2015342869A patent/AU2015342869A1/en not_active Abandoned
- 2015-11-06 RU RU2017119065A patent/RU2727802C2/ru active
- 2015-11-06 HU HUE15795318 patent/HUE044557T2/hu unknown
- 2015-11-06 EP EP15795318.3A patent/EP3215158B1/en not_active Not-in-force
- 2015-11-06 CA CA2966359A patent/CA2966359A1/en not_active Abandoned
- 2015-11-06 EP EP19171060.7A patent/EP3581184B1/en not_active Not-in-force
- 2015-11-06 WO PCT/US2015/059512 patent/WO2016073877A1/en not_active Ceased
- 2015-11-06 JP JP2017543329A patent/JP6705828B2/ja not_active Expired - Fee Related
- 2015-11-06 KR KR1020177015388A patent/KR20170098812A/ko not_active Ceased
- 2015-11-06 US US15/524,844 patent/US10206910B2/en active Active
- 2015-11-06 ES ES15795318T patent/ES2741399T3/es active Active
- 2015-11-06 PL PL15795318T patent/PL3215158T3/pl unknown
- 2015-11-06 CN CN201580072608.8A patent/CN107249638B/zh not_active Expired - Fee Related
- 2015-11-06 MX MX2017006015A patent/MX377593B/es active IP Right Grant
- 2015-11-06 PT PT15795318T patent/PT3215158T/pt unknown
-
2017
- 2017-04-24 IL IL251905A patent/IL251905B/en active IP Right Grant
-
2018
- 2018-12-19 US US16/226,175 patent/US20190201385A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,814 patent/US11166944B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535601A5 (enExample) | ||
| RU2017119065A (ru) | Апилимод для применения в лечении рака почек | |
| WO2015154064A3 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| JP2018525358A5 (enExample) | ||
| WO2021053667A3 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| HRP20200696T1 (hr) | Terapija u kombinaciji s inhibitorom topoizomeraze | |
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| JP2017535600A5 (enExample) | ||
| JP2017533963A5 (enExample) | ||
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| JP2017517520A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| FI3618875T3 (fi) | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2018516911A5 (enExample) | ||
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| MX372942B (es) | Derivados de 1-(5-terc-butil-2-aril-pirazol-3-il)-3-[2-fluoro-4-[(3-oxo-4h-pirido[2,3 b]piracin-8-il)oxi]fenil]urea como inhibidores de raf para el tratamiento del cancer. | |
| MY150993A (en) | Pyrimidine substituted purine derivatives | |
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| IL276434B2 (en) | Combination therapy involving antibodies against claudin 18.2 for the treatment of cancer | |
| JP2018508593A5 (enExample) | ||
| Minguet et al. | Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives | |
| WO2008116053A3 (en) | Fap-activated chemotherapeutic compounds, and methods of use thereof | |
| RU2018105923A (ru) | Способы лечения рака с использованием апилимода |